A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 21 Aug 2019 Status changed from not yet recruiting to recruiting.
- 16 Jul 2019 Planned initiation date changed from 31 May 2019 to 31 Jul 2019.
- 16 May 2019 Planned End Date changed from 1 May 2021 to 1 May 2022.